2024-516786-37-00尚未招募1 期
HER2-Targeting Site-Specific Labelled 89Zr-Trastuzumab PET Imaging of Patients with Cancer
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 140
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Andreas Kjær
Scientific
Rigshospitalet
研究点 (1)
Loading locations...
相似试验
招募中
1 期
HER2-PET Imaging in HER2-low Breast CancersBreast Cancer MetastaticNCT06732336Centre de recherche du Centre hospitalier universitaire de Sherbrooke40
进行中（未招募）
1 期
[89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; A multicentre studyEUCTR2018-004247-23-NLeiden University Medical Center20
招募中
不适用
[89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; a multicentre studyHER2 positive primary breast cancerNL-OMON28319eiden University Medical Center (LUMC)20
终止
2 期
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerHER2-positive Metastatic Breast CancerHER2-positive Advanced Breast CancerNCT06595563Jules Bordet Institute87
进行中（未招募）
不适用
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study - TRAIN studyHER2 positive breat cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-000987-18-NLetherlands Cancer Institute